Nivolumab improved significantly OS in the first-line when added to chemotherapy and may develop as a new standard for the first-line treatment of gastric and GEJ adenocarcinoma with a PD-L1 CPS ≥ 5. This evidence concerns the gene CD274 and gastroesophageal junction adenocarcinoma.